Datavault AI has expanded its strategic licensing agreement with DataMeds AI to extend its PharmacyChain blockchain technology beyond pharmaceutical distribution into broader healthcare, healthspan, and wellness applications. The amended agreement strengthens both companies' collaboration around patient-controlled healthcare data, AI-powered data monetization, and real-world asset (RWA) tokenization.
The expanded partnership aims to support secure healthcare data transactions across pharmacy, medical, laboratory, and wearable ecosystems while enabling organizations to unlock new commercial opportunities through data ownership and monetization technologies.
Quick Intel
Datavault AI announced an amendment to its definitive agreement with DataMeds AI, expanding the scope of its PharmacyChain blockchain-related technology licensing relationship. While the original collaboration focused on pharmaceutical distribution, the revised agreement now includes commercial healthcare, healthspan, and wellness applications utilizing Datavault AI's intellectual property.
The expanded partnership follows DataMeds' ongoing acquisition of a behavioral healthcare patent portfolio covering medical logistics, IoT-enabled population health, remote patient monitoring, and AI-driven behavioral healthcare technologies.
The companies plan to extend Datavault AI's data monetization platform and real-world asset tokenization technologies into DataMeds' healthcare ecosystem. The initiative is intended to enable patient-controlled access to medical information while supporting secure healthcare data transactions across multiple care environments, including pharmacies, laboratories, healthcare providers, and wearable devices.
“Our business model depends on extracting greater value from the information we generate every day. Datavault AI’s platform gives us confidence that we can transform data into a strategic asset for our future customers, not just for operational insights, but as a foundation for future commercial opportunities and customer acquisition strategies. We see this as the key step in modernizing how organizations think about data ownership and monetization in healthcare,” said Gerald Commissiong, Interim Co-CEO of DataMEDS.
Nathaniel T. Bradley, CEO of Datavault AI, said, “Extending our data monetization and tokenization platform into commercial healthcare, healthspan and wellness is a natural next step for patient-controlled data. DataMEDS gives us a focused path to put that technology to work so individuals have a say over how their own medical information is transacted.”
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMeds' outstanding common stock instead of preferred shares upon completion of previously announced related transactions.
According to the companies, the amendment was made to optimize the transaction from a tax perspective. Completion remains subject to several closing conditions, including the acquisition of intellectual property portfolios from EOS Technology Holdings and a controlling interest in Tollo Health LLC.
The value of the common shares issued to Datavault AI is expected to be recognized as revenue upon issuance.
The expanded relationship reflects growing demand for AI-enabled healthcare data management and blockchain-based data ownership models. The companies highlighted the increasing volume of healthcare data globally and the commercial potential of patient-controlled data monetization within the multi-trillion-dollar global health and wellness market.
By extending the agreement before all closing conditions are completed, Datavault AI and DataMeds aim to accelerate operational collaboration and provide earlier access to Datavault AI's technology ecosystem while preparing broader commercialization efforts.
DataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here Mobile application and Tollo Health.
Datavault AI™ (NASDAQ: DVLT) leads AI-driven data experiences, valuation, and monetization in the Web 3.0 environment. The Company’s cloud-based platform delivers comprehensive solutions through its collaborative Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division includes WiSA®, ADIO®, and Sumerian® patented technologies for spatial and multichannel wireless HD sound. The Data Science Division harnesses Web 3.0 and high-performance computing for experiential data perception, valuation, and secure monetization across industries including sports & entertainment, biotech, education, fintech, real estate, healthcare, and energy. The Information Data Exchange® (IDE) enables Digital Twins and secure NIL licensing, fostering responsible AI with integrity. Datavault AI’s customizable technology suite offers AI/ML automation, third-party integration, analytics, marketing automation, and advertising monitoring.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones, and thrive on the tech pulse.
